The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The advances in the treatment of retinoblastoma have enabled salvaging the globe in advanced stages with intra-arterial chemotherapy (IAC). We developed a strategy of alternate application of systemic intravenous chemotherapy (IVC) and IAC (referred to as alternate systemic IVC and IAC; ASIAC) to reduce central nervous metastases during IAC and examined its efficacy and safety in eye globe salvage in this study.Materials and Methods Between January 2010 and February 2021, 43 eyes of 40 patients received ASIAC treatment for retinoblastoma at the Yonsei Cancer Center, Yonsei University Health System. Their medical records were reviewed retrospectively to evaluate the eye salvage rate (ESR), defined from diagnosis to enucleation. High-risk retinoblastoma was defined as group D or E by the International Classification of Retinoblastoma.Results The study enrolled 38 and five cases of high-risk and low-risk retinoblastoma, respectively. In total, 178 IAC and 410 IVC courses were administered, with a median of 4 (interquartile range [IQR], 3.0 to 5.0) IAC and 9 (IQR, 6.0 to 11) IVC courses per eye, respectively. The 5-year ESR was 60.4%±8.7% for the whole cohort, 100% for low-risk retinoblastoma, and 53.6%±9.8% for high-risk retinoblastoma. Among those diagnosed since 2015, the 5-year ESR for high-risk retinoblastoma was 63.5%±14.0%. Fifteen eyes underwent enucleation; no viable tumor was found in three enucleated eyes. There were no deaths in this cohort.Conclusion Primary IAC-IVC (i.e., ASIAC) for patients with retinoblastoma was tolerable and effective in salvaging the eye and maintaining survival.
Abstract
Purpose The advances in the treatment of retinoblastoma have enabled salvaging the globe in advanced stages with intra-arterial chemotherapy (IAC). We developed a strategy of alternate application of systemic intravenous chemotherapy (IVC) and IAC (referred to as alternate systemic IVC and IAC; ASIAC) to reduce central nervous metastases during IAC and examined its efficacy and safety in eye globe salvage in this study.Materials and Methods Between January 2010 and February 2021, 43 eyes of 40 patients received ASIAC treatment for retinoblastoma at the Yonsei Cancer Center, Yonsei University Health System. Their medical records were reviewed retrospectively to evaluate the eye salvage rate (ESR), defined from diagnosis to enucleation. High-risk retinoblastoma was defined as group D or E by the International Classification of Retinoblastoma.Results The study enrolled 38 and five cases of high-risk and low-risk retinoblastoma, respectively. In total, 178 IAC and 410 IVC courses were administered, with a median of 4 (interquartile range [IQR], 3.0 to 5.0) IAC and 9 (IQR, 6.0 to 11) IVC courses per eye, respectively. The 5-year ESR was 60.4%±8.7% for the whole cohort, 100% for low-risk retinoblastoma, and 53.6%±9.8% for high-risk retinoblastoma. Among those diagnosed since 2015, the 5-year ESR for high-risk retinoblastoma was 63.5%±14.0%. Fifteen eyes underwent enucleation; no viable tumor was found in three enucleated eyes. There were no deaths in this cohort.Conclusion Primary IAC-IVC (i.e., ASIAC) for patients with retinoblastoma was tolerable and effective in salvaging the eye and maintaining survival.
참고문헌 (34)
- Dimaras H, "Retinoblastoma", Lancet, 379, pp.1436~1446 (2012)
- Abramson DH, "Treatment of retinoblastoma in 2015 : agreement and disagreement", JAMA Ophthalmol, 133, pp.1341~1347 (2015)
- Kim JW, "Current management strategies for intraocular retinoblastoma", Drugs, 67, pp.2173~2185 (2007)
- 김혜리, "Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience", Cancer Research and Treatment, 40(4), pp.164~171 (2008), 대한암학회
- Gobin YP, "Intra-arterial chemotherapy for the management of retinoblastoma : four-year experience", Arch Ophthalmol, 129, pp.732~737 (2011)
- Shields CL, "Intra-arterial chemotherapy for retinoblastoma in 70 eyes : outcomes based on the internatio-nal classification of retinoblastoma", Ophthalmology, 121, pp.1453~1460 (2014)
- Suzuki S, "Management of intraocular retinoblastoma and ocular prognosis", Int J Clin Oncol, 9, pp.1~6 (2004)
- Ravindran K, "Intra-arterial chemotherapy for retinoblastoma : an updated systematic review and meta-analysis", J Neurointerv Surg, 11, pp.1266~1272 (2019)
- Yousef YA, "Intra-arterial chemotherapy for retinoblastoma : a systematic review", JAMA Ophthalmol, 134, pp.584~591 (2016)
- Khelfaoui F, "Histopathologic risk factors in retinoblastoma : a retrospective study of 172 patients treated in a single institution", Cancer, 77, pp.1206~1213 (1996)
- Singh L, "Update on pathology of retinoblastoma", Int J Ophthalmol, 11, pp.2011~2016 (2018)
- Sastre X, "Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma", Arch Pathol Lab Med, 133, pp.1199~1202 (2009)
- Kaliki S, "Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma", Arch Ophthalmol, 129, pp.1422~1427 (2011)
- Chevez-Barrios P, "Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy : a Children’s Oncology Group study", J Clin Oncol, 37, pp.2883~2891 (2019)
- Pekacka A, "The role of intraarterial chemotherapy in the management of retinoblastoma", J Ophthalmol, 2020, pp.3638410~ (2020)
- Jabbour P, "Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma", J Neurosurg Pediatr, 10, pp.175~181 (2012)
- Hahn SM, "Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma", Pediatr Hematol Oncol, 33, pp.74~82 (2016)
- 최새롬, "Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma", Clinical and Experimental Pediatrics, 56(6), pp.254~259 (2013), 대한소아청소년과학회
- Lee DH, "Changes in treatment patterns and globe salvage rate of advanced retinoblastoma in Korea : efficacy of intra-arterial chemotherapy", J Clin Med, 10, pp.5421~ (2021)
- Berry JL, "Response criteria for intraocular retinoblastoma : RB-RECIST", Pediatr Blood Cancer, 68, pp.e28964~ (2021)
- Chen Q, "Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma", Cancer Chemother Pharmacol, 85, pp.723~730 (2020)
- Xu K, "Intra-arterial chemotherapy combined with VEC intravenous chemotherapy in the treatment of advanced retinoblastoma", J BUON, 25, pp.1199~1205 (2020)
- Marr BP, "Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma : preliminary results", Br J Ophthalmol, 96, pp.1300~1303 (2012)
- Shields CL, "Retinoblastoma control with primary intra-arterial chemotherapy : outcomes before and during the intravitreal chemotherapy era", J Pediatr Ophthalmol Strabismus, 53, pp.275~284 (2016)
- Grigorovski N, "Use of intra-arterial chemotherapy for retinoblastoma : results of a survey", Int J Ophthalmol, 7, pp.726~730 (2014)
- Scelfo C, "An international survey of classification and treatment choices for group D retinoblastoma", Int J Ophthalmol, 10, pp.961~967 (2017)
- Monroy JE, "Complications of intra-arterial chemotherapy for retinoblastoma", Semin Ophthalmol, 29, pp.429~433 (2014)
- de Graaf P, "Guidelines for imaging retinoblastoma : imaging principles and MRI standardization", Pediatr Radiol, 42, pp.2~14 (2012)
- Shields CL, "Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors", Arch Ophthalmol, 127, pp.282~290 (2009)
- Friedman DL, "Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma(ARET0331) : a report from the Children’s Oncology Group", Pediatr Blood Cancer, 64, pp.e26394~ (2017)
- Ghassemi F, "Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant therapy", Pediatr Blood Cancer, 60, pp.599~604 (2013)
- Francis JH, "Ten-year experience with ophthalmic artery chemosurgery : ocular and recurrence-free survival", PLoS One, 13, pp.e0197081~ (2018)
- Global Retinoblastoma Study Group, "Global retinoblastoma presentation and analysis by national income level", JAMA Oncol, 6, pp.685~695 (2020)
- Park SJ, "Incidence of retinoblastoma and survival rate of retinoblastoma patients in Korea using the Korean National Cancer Registry database(1993-2010)", Invest Ophthalmol Vis Sci, 55, pp.2816~2821 (2014)